“I do think this [approval] represents a step forward for patients who have the FLT3 mutation in association with their [AML] over the previous standard, midostaurin [Rydapt],” study author @MikkaelSekeres, MD, said in an interview with CancerNetwork ahead of the approval. https://t.co/nqtM6JI5dz (@CancerNetwrk)

WATCH: Ashwin Kishtagari, MD, discusses the PERSIST-2 trial of pacritinib for patients with primary #myelofibrosis and low platelet counts. #mpnsm | @AshKishtagari @VUMC_Cancer https://t.co/P26dOHuSFB (@TargetedOnc)

For me this question is crystal clear. There is a wealth of evidence showing that GO provides a large significant improvement in OS in patients with CBF-AML. Benefit of midostaurin is modest overall, and data is limited in patients with CBF-AML. So 7+3 + GO or FLAG-GO, no doubt. (@grichardmd)

Quizartinib Plus Chemotherapy Improves EFS, RFS in Newly Diagnosed FLT3-ITD–Negative AML @HospitalLaFe @EHA_Hematology #EHA2023 #leusm https://t.co/a1LH4dEPxB (@OncLive)

Treatment w/ pacritinib demonstrated comparable improvements in spleen and symptom response regardless of baseline platelet counts and hemoglobin levels, according to the PERSIST-1 and PERSIST-2 trials. @doctorpemm @MDAndersonNews #ASCO23 #mpnsm https://t.co/Vlx0uZtwUE (@OncLive)

Treatment w/ pacritinib demonstrated comparable improvements in spleen and symptom response regardless of baseline platelet counts and hemoglobin levels, according to the PERSIST-1 and PERSIST-2 trials. @doctorpemm @MDAndersonNews #ASCO23 #mpnsm https://t.co/3Nn7kNTmpG (@OncLive)

11/19 #TumorBoardTuesday #Sarcoma 👩🏻‍🏫Mini tweetorial 8👨🏻‍🏫 ✨INVICTUS (cont’d)✨ 📌Ripretinib (RI) ▪️mPFS 6.3m (RI) vs 1.0m (placebo); p<0.0001 ▪️common AEs: 🧑‍🦲,💪🏼😫,🤢,😴 📚@jeanyvesblay @DrCeSarcoma https://t.co/i4ec7ZBOZE (@SteveBialickDO)

10/19 #TumorBoardTuesday #Sarcoma 👩🏻‍🏫Mini tweetorial 7👨🏻‍🏫 ✨INVICTUS✨ 📌Ripretinib (RI), a switch-control TKI 🙌🏼shows efficacy/safety in 4L+ adv #GIST ▪️ph 3, multicenter ▪️dbl-blnd ➡️ plcbo-ctrl trial ▪️2:1 RI vs plcbo after prog (or intol) with IM, SU, & RE (@SteveBialickDO)

Pacritinib Provides Spleen, Symptom Reduction Regardless of Blood Counts, Association Between SVR and OS in Myelofibrosis @doctorpemm @MDAndersonNews @ASCO #ASCO2023 #ASCO23 #mpnsm https://t.co/0e7noVqafb (@OncLive)

Our Dr. Naveen Pemmaraju discusses the Phase III PERSIST-2 clinical trial showing pacritinib to be an effective JAK inhibitor in patients with low platelet counts. Watch to learn about the findings here: https://t.co/6meqYo0xQ6 @OncLive @doctorpemm #Leukemia #EndCancer (@MDAndersonNews)

This was helpful, particularly the cell + blood cancer explanation. Our child must be a unicorn, because she's BRAF neg and cobi didn't work... Luckily a CSF1R mutation was found, and it turned out to be targetable. Complete response to pexidartinib. (@onecolleen)

El doctor Pau Montesinos ha expuesto hoy en #EHA2023: Preliminary results of QUIWI: doble blinded, randomized clinical trial comparing standard chemotherapy plus quizartinib versus placebo in adult patients with newly diagnosed FLY3-ITD wild-type AML Fotos de gráficas @noriega_dr (@_pethema)

7068 Bose: Wouldn't be PROs without myelofibrosis! Significant improvement in symptom burden with pacritinib in MF, with ~80% of pts reporting improvement by week 24. Improvement regardless of cytopenias. https://t.co/IWCDtrKLgj #mpnsm #ASCO23 (@majorajay)

CONGRESS| #ASCO23 | Poster Prithviraj Bose (@bose_prithviraj) of @MDAndersonNews describes data across PERSIST-1 and PERSIST-2 trials showing the consistent efficacy of pacritinib for spleen reduction and symptom improvements in pts with MF regardless of cytopenias #MPN #MPNsm (@MPN_Hub)

👉👉👉#ASCO23 Pacritinib effective at key MF endpoints of reducing splenomegaly & improving symptoms regardless of cytopenias presented by #MPNWarrior ⁦@bose_prithviraj⁩ ! ⁦@MDAndersonNews⁩ ⁦@doctorpemm⁩ ⁦@MDmasarova⁩ ⁦@Daver_Leukemia⁩ #mpnsm (@mpdrc)

#ASCO23 #sarcoma Approvals of TKIs for GIST! Unfortunately, in Brazil, no changes since 2013. We must press for global access to newer TKIs including ripretinib and avapritinib. (@PestanaRC)

PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AML https://t.co/XnnE9FHzcR #leusm #AML #EHA23 (@smbenlazar)

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial https://t.co/vmh6ve49yp (@albertomussetti)

PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE #AML EHA Library; Jun 08 2023; 387830 https://t.co/XnnE9FHzcR #EHA23 (@smbenlazar)

OS hazard ratio vs 7+3 is almost identical to midostaurin in RATIFY, plus there are safety concerns with quizartinib (arrhythmias) that already contributed to its non-approval in R/R AML. Who among my colleagues would favor quiz over mido in first line, and why? (@KlausMetzelerMD)

Cantor #Biotechs Cantor Hosting:Virtual KOL Call discuss Key Takeaways #EHA23 June 12 11AM ET •Menin inhibitor space $KURA $SNDX $APTO tuspetinib for FLT3m, FLT3- Therapies for T-cell lymphomas: $AFMD innate cell engager AFM13 mono + NK-cell combo, $CRVS ITK-inhibitor CPI-818 (@semodough)

This is very impressive I think 😮 Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial https://t.co/tqJ4qEMXsp (@GvHD_Meade)

FLT3、KIT、CSF1を阻害する #NMS088 が、FLT3阻害薬の投与歴がある #FLT3変異 陽性の再発・難治性 #急性骨髄性白血病（#AML）に有用である可能性が明らかとなりました。 #AACR23 https://t.co/OVLDIm1tgO (@cancer_navi)

I am happy to share our manuscript on the dual SYK/FLT3 inhibitor mivavotinib in relapsed AML. While in AML modest clinical activity was revealed, the discovery of bleeding events associated with SYKi mediated platelet inactivation is important finding. https://t.co/PvkTG6SSQ2 (@PratzKW)

Quizartinib + CT vs Placebo + CT in Newly Diagnosed FLT3-Mutant #AML (@smbenlazar)

Let me correct the the title. Quizartinib improved OS compared to a regimen we would not use in the United States to treat FLT mutated AML Phase III Trial Reports Quizartinib Doubles Overall Survival in FLT3-ITD–Positive AML - The ASCO Post https://t.co/VnrDLy3IOd (@AaronGoodman33)

Filip Janku, MD, PhD, discusses the phase 1 study with ripretinib in patients with KIT-mutated or KIT-amplified melanoma. @FilipJankuMD @UTHealthSAMDA #melsm https://t.co/0HDoC88Nm5 (@OncLive)

The efficacy seen with ripretinib in patients with KIT-mutated melanoma was higher than has been previously reported @FilipJankuMD @UTHealthSAMDA #melsm https://t.co/AxIs2YBpl7 (@OncLive)

Was that a question or a comment? 🤔 great presentation @musayilmaz54 !! Exciting data on Quizartinib in the FLT3 mutated R/R AML population! (@aditishasMD)

Ripretinib Demonstrates Impressive Efficacy, Durability in Heavily Pretreated KIT-Mutated Melanoma @FilipJankuMD @UTHealthSAMDA #melsm https://t.co/ZRxXWkpXAZ (@OncLive)

Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor #GIST harboring heterogenous KIT/PDGFRA mutations ⁦@seppobauer⁩ ⁦@schoffski⁩ ⁦@jeanyvesblay⁩ ⁦@GinaDAmatoMD1⁩ ⁦@SylvesterCancer⁩ https://t.co/rwLy6Gh01X (@JTrentMDPhD)

Cup cells 🥃 NPM1, FLT3 AML 👌🏻 (@HarbyKhalid)

Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial https://t.co/Np57Bz7aTv via @rightrelevance thanks @viveksubbiah (@ChocolatiereP)

Harry P. Erba, MD, PhD, @DukeMedSchool ; Amir Fathi, MD, @MassGeneralNews ; Mark J. Levis, MD, PhD, @HopkinsMedicine ; Gail J. Roboz, MD, @WeillCornell ; and @DanPollyea , MD, MS, @CUDenver discuss FLT3 genetic alterations in AML #leusm https://t.co/AzjMWuzS7r (@OncLive)

AML with NPM1 and/or FLT3 mutation (@kitagawa_yukiko)

During #TCTM21, the @AML_Hub spoke to @nagler_EBMT, @TAUMedFaculty. We asked, How does cytogenetic risk affect outcome of allo-SCT in patients with FLT3+ NPM1– AML? Watch the interview to find out 👉 https://t.co/NcYKMZarTt #leusm #leukemia #AML (@AML_Hub)

CONGRESS | #TCTM21 | @nagler_EBMT, Chaim Sheba Medical Center, reports an association between cytogeneic risk and outcome for FLT3+ NPM1- AML patients undergoing alloSCT → cytogenetic risk is an important prognosticator #leusm #Leukemia (@AML_Hub)

How do FLT3 mutations, IDH1/2 mutations, and other biomarkers influence the selection of therapy for acute #leukemia? Find out now from Dr. Courtney DiNardo from @MDAndersonNews #beyondthecongress #beyondASH21 (@BioAscend)

In episode 2, @Daver_Leukemia speaks about the use of venetoclax combinations in FLT3 mutation subtypes of AML. https://t.co/Fjx9Jtw448 #leusm #leukemia (@AML_Hub)

#ASH20 || #LBA3. Outstanding presentation by Dr Lindsey Montefiori PhD 👉 #BCL11B defines a new subtype of lineage ambiguous acute leukemia #leusm #ASHKudos | Notably 80% in this novel group had #FLT3 alterations. @ASH_hematology (@doctorpemm)

6)Finally, resistance profiles after FLT3 TKI from Dr. Alotaibi and @Daver_Leukemia: Large cohort (67 pts with secondary and 106 with primary FLT3 TKI resistance). TKD mutations more common after Type II TKI (~30% pts), RAS/MAPK mutations more common after Type I (~30% of pts). (@SmithLabSF)

Happy to share the recently published paper @BCD_AACR presented at #ASH20 @AAlotaibi_MD @Daver_Leukemia where they describe mutations that emerge at relapse after FLT3-i Tx https://t.co/s4PGtxzxy7, and check our commentary @aditishasMD @Amitvermamds https://t.co/S9Ao9EbGyy (@LugoMd)